A Meta-Analysis of Two Double-Blind, Placebo Controlled, Randomized Trials to Evaluate the Efficacy and Safety of Carvedilol Treatment in Non-Dialysis Dependent Chronic Kidney Disease Patients with Symptomatic or Asymptomatic Systolic Heart Failure

R. Wali; M. Iyengar; D. Chartyan; M.A. Lukas; C. Cooper; A. Cheung

doi:10.1016/j.cardfail.2009.06.043

A Meta-Analysis of Two Double-Blind, Placebo Controlled, Randomized Trials to Evaluate the Efficacy and Safety of Carvedilol Treatment in Non-Dialysis Dependent Chronic Kidney Disease Patients with Symptomatic or Asymptomatic Systolic Heart Failure

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2009.06.043 ◽

2009 ◽

Vol 15 (6) ◽

pp. S116

Author(s):

R. Wali ◽

M. Iyengar ◽

D. Chartyan ◽

M.A. Lukas ◽

C. Cooper ◽

...

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Randomized Trials ◽

Meta Analysis ◽

Systolic Heart Failure ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70208-0 ◽

2014 ◽

Vol 2 (5) ◽

pp. 369-384 ◽

Cited By ~ 308

Author(s):

Anthony H Barnett ◽

Ambrish Mithal ◽

Jenny Manassie ◽

Russell Jones ◽

Henning Rattunde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718462631.793518344 ◽

2016 ◽

Author(s):

Sydney Tang ◽

Gary Chan

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis

Pediatric Nephrology ◽

10.1007/s00467-018-4116-y ◽

2018 ◽

Vol 34 (3) ◽

pp. 475-486 ◽

Cited By ~ 6

Author(s):

Bradley A. Warady ◽

Janet N. Iles ◽

Gema Ariceta ◽

Bastian Dehmel ◽

Guillermo Hidalgo ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Secondary Hyperparathyroidism ◽

Pediatric Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954671.793466054 ◽

2012 ◽

Author(s):

John Eisman

Keyword(s):

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Controlled Trial ◽

High Dose ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of mineralocorticoid receptor antagonists in patients with heart failure and chronic kidney disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737121012.793571782 ◽

2020 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Mineralocorticoid Receptor ◽

Efficacy And Safety ◽

Mineralocorticoid Receptor Antagonists ◽

Receptor Antagonists ◽

Patients With Heart Failure

Download Full-text

Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: a meta-analysis of cardiovascular outcomes trials

Diabetes & Metabolism ◽

10.1016/j.diabet.2021.101249 ◽

2021 ◽

pp. 101249

Author(s):

Julian W. Sacre ◽

Dianna J. Magliano ◽

Jonathan E. Shaw

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Meta Analysis ◽

Cardiovascular Outcomes ◽

Heart Failure Hospitalisation

Download Full-text

Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: a systematic review and meta‐analysis

British Journal of Clinical Pharmacology ◽

10.1111/bcp.15055 ◽

2021 ◽

Author(s):

Li Zheng ◽

Jinhui Tian ◽

Deping Liu ◽

Yan Zhao ◽

Xiaoyong Fang ◽

...

Keyword(s):

Systematic Review ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Meta Analysis ◽

Efficacy And Safety

Download Full-text

FP413EFFECT OF VITAMIN D SUPPLEMENTATION ON VASCULAR FUNCTION, ENDOTHELIAL AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfv177.12 ◽

2015 ◽

Vol 30 (suppl_3) ◽

pp. iii205-iii208

Author(s):

Ashok Kumar Yadav ◽

Vivek Kumar ◽

Vinod Kumar ◽

Manphool Singhal ◽

Anupam Lal ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Vitamin D ◽

Kidney Disease ◽

Vascular Function ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Inflammatory Biomarkers ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

The Lancet ◽

10.1016/s0140-6736(11)61126-4 ◽

2011 ◽

Vol 378 (9792) ◽

pp. 676-683 ◽

Cited By ~ 216

Author(s):

John GF Cleland ◽

John R Teerlink ◽

Roxy Senior ◽

Evgeny M Nifontov ◽

John JV Mc Murray ◽

...

Keyword(s):

Heart Failure ◽

Cardiac Function ◽

Systolic Heart Failure ◽

Phase 2 ◽

Cardiac Myosin ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Omecamtiv Mecarbil ◽

Dose Ranging

Download Full-text